Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | KLK6 | Q92876 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12024540 | 0.79 | KDM4E (0.44) | LMNAKDM4EKLK6SMN1; SMN2ALDH1A1 | |
| SCHEMBL3921386 | 0.76 | HTT (0.39) | KDM4ESMN1; SMN2ALDH1A1TSHRPKM | |
| SCHEMBL1939157 | 0.75 | KLK6 (0.54) | LMNAKDM4EKLK6SMN1; SMN2ALDH1A1 | |
| SCHEMBL368035 | 0.73 | PKM (0.63) | LMNAKDM4ESMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL1940624 | 0.73 | EGFR (0.45) | LMNAKDM4EKLK6SMN1; SMN2ALDH1A1 | |
| SCHEMBL9535451 | 0.72 | MEN1 (0.59) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR | |
| SCHEMBL3380080 | 0.70 | HSD17B10 (0.65) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL29419554 | 0.70 | SMN1; SMN2 (0.49) | LMNAKDM4ESMN1; SMN2ALDH1A1HSD17B10 | |
| SCHEMBL16464368 | 0.69 | ALDH1A1 (0.48) | LMNAKDM4EALDH1A1HSD17B10TSHR | |
| SCHEMBL16464155 | 0.69 | HTR6 (0.51) | KDM4ESMN1; SMN2ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301168-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | LMNA 3021/4885KDM4E 4697/4885KLK6 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.